TG THERAPEUTICS, INC. Increase (Decrease) in Inventories
TG THERAPEUTICS, INC. (TGTX) reported Increase (Decrease) in Inventories of $80.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-05
- TG THERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2026-06-30 was $66.82M.
- TG THERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2026-03-31 was $13.28M, a 71.33% decline year-over-year.
- TG THERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was -$563.00K, a 102.27% decline year-over-year.
- TG THERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was -$8.70M, a 442.32% decline year-over-year.
- TG THERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2025 was $33.45M, a 49.96% decline from fiscal 2024.
- TG THERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2024 was $66.85M, a 80.98% increase from fiscal 2023.
- TG THERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2023 was $36.94M.
- TG THERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | $66.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $80.10M 10-Q · filed 2026-08-05 | $79.54M derived: sum of 3 quarters · filed 2026-08-05 | $70.84M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $13.28M 10-Q · filed 2026-05-06 | $12.71M derived: sum of 2 quarters · filed 2026-05-06 | $4.02M derived: sum of 3 quarters · filed 2026-05-06 | $422.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$563.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$9.26M derived: sum of 2 quarters · filed 2026-02-27 | -$12.85M derived: sum of 3 quarters · filed 2026-08-05 | $33.45M 10-K · filed 2026-02-27 |
| 2025-09-30 | -$8.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$12.29M derived: sum of 2 quarters · filed 2026-08-05 | $34.02M 10-Q · filed 2025-11-05 | $58.84M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $42.71M 10-Q · filed 2026-08-05 | $67.53M derived: sum of 3 quarters · filed 2026-08-05 | $70.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $46.30M 10-Q · filed 2026-05-06 | $71.13M derived: sum of 2 quarters · filed 2026-05-06 | $73.67M derived: sum of 3 quarters · filed 2026-05-06 | $76.22M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $24.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $27.36M derived: sum of 2 quarters · filed 2026-02-27 | $29.92M derived: sum of 3 quarters · filed 2026-02-27 | $66.85M 10-K · filed 2026-02-27 |
| 2024-09-30 | $2.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.10M derived: sum of 2 quarters · filed 2025-11-05 | $42.03M 10-Q · filed 2025-11-05 | $47.54M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $2.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $39.49M 10-Q · filed 2025-08-08 | $45.00M derived: sum of 3 quarters · filed 2026-02-27 | $47.53M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $36.93M 10-Q · filed 2025-05-09 | $42.44M derived: sum of 2 quarters · filed 2026-02-27 | $44.97M derived: sum of 3 quarters · filed 2026-02-27 | $46.95M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $5.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $8.04M derived: sum of 2 quarters · filed 2026-02-27 | $10.01M derived: sum of 3 quarters · filed 2026-02-27 | $36.94M 10-K · filed 2026-02-27 |
| 2023-09-30 | $2.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $4.51M derived: sum of 2 quarters · filed 2024-11-07 | $31.43M 10-Q · filed 2024-11-07 | $31.43M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $1.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $28.90M 10-Q · filed 2024-08-09 | $28.90M derived: sum of 3 quarters · filed 2025-03-03 | |
| 2023-03-31 | $26.92M 10-Q · filed 2024-05-06 | $26.92M derived: sum of 2 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $0.00 10-K · filed 2025-03-03 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-06 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |